SQUARE LEAGUE

Indo Farm Equipment IPO: GMP, Key Insights, Financial Highlights, and Investment Potential

Investment Opportunities in the Agri Sector

The upcoming IPO will be open for bidding from December 31, 2024 to January 2, 2025, with a price range of ₹204-215 per share. Investors must bid for a minimum lot size of 69 shares, requiring a minimum investment of ₹14,076. The total issue size is ₹260.15 crores.

Indo Farm Equipment Ltd. (IFEL), established in 1994, is a Chandigarh-based manufacturer specializing in tractors, pick-and-carry cranes, and other agricultural machinery. The company offers a diverse range of tractors from 16 HP to 110 HP and cranes with capacities ranging from 9 to 30 tons. Their products are marketed under the brand names “INDO FARM” for tractors and “INDO POWER” for cranes. Additionally, IFEL operates an asset financing business through its wholly-owned subsidiary, Barota Finance Limited, a registered Non-Banking Financial Company (NBFC) specializing in retail financing of tractors.

IFEL’s manufacturing facility is located in Baddi, Himachal Pradesh, covering over 127,840 square meters. This fully integrated setup includes a captive foundry unit and dedicated units for the machining, fabrication, and assembly of both tractors and cranes. The current production capacity is 12,000 tractors and 1,280 cranes annually, with plans to expand crane production by an additional 3,600 units per year to meet growing demand.

The IPO consists of a total of 12,100,000 equity shares, which includes a fresh issue of up to 8,600,000 equity shares and an offer for sale of up to 3,500,000 equity shares by the promoter Ranbir Singh Khadwalia. The face value of each equity share is ₹10 . The bid/offer period is scheduled to open on December 31, 2024 and close on January 02, 2025. The company has undertaken a pre-IPO placement of 1,900,000 Equity Shares at ₹185 per share, which has reduced the size of the fresh issue. The offer will constitute 25.18% of the fully diluted post-offer paid-up equity share capital of the company. As of December 30, 2024, the shares are trading at a premium of approximately ₹75-80, indicating a 35% increase over the upper price band.

The net proceeds from the fresh issue are planned for several key purposes. A significant portion, ₹70.074 crore, is designated for establishing a new, dedicated unit to expand the company’s pick and carry crane manufacturing capacity. This expansion aims to meet the high demand for the company’s cranes and to fully utilise their manufacturing capabilities. Additionally, ₹50 crore is allocated for the repayment or prepayment of certain borrowings, which the company expects will reduce their outstanding debt and improve their debt-to-equity ratio. A further ₹45 crore will be invested in their NBFC subsidiary, Barota Finance Ltd., to increase its capital base and enable it to meet future capital requirements. The remaining net proceeds will be used for general corporate purposes, including strategic initiatives, partnerships, acquisitions, and meeting the company’s operational needs. The amount used for general corporate purposes will not exceed 25% of the gross proceeds of the offer. The company has already utilised ₹33.77 crores from a pre-IPO placement for general corporate purposes.

Financial Insights

Indo Farm Equipment Limited demonstrates a consistent pattern of growth and profitability, although its profit margins remain relatively modest. In fiscal year 2024, the company achieved a revenue of ₹375.23 crore. The company’s profit after tax (PAT) was ₹15.60 crore in the same fiscal year, highlighting its ability to generate profits, though the margins are not particularly high. The company’s PAT margin was 4.16% in 2024, this demonstrates a steady profitability, though it is important to note that the company has seen similar profit margins in previous fiscal years, which indicates consistent operational performance.

The company’s operational efficiency is reflected in its EBITDA of ₹62.52 crore in fiscal year 2024. The company’s return on equity (RoE) was 5.13% and its return on capital employed (RoCE) was 8.96% for the same period. These ratios measure the company’s effectiveness in utilising shareholder investments and capital, respectively. The company’s debt-to-equity ratio stood at 0.01 as of March 31, 2024, indicating that the company has its debt in relation to its equity under control.

The company’s Net Asset Value (NAV) per share was ₹84.43 as of March 31, 2024, which is a measure of the company’s net asset value on a per-share basis. The company’s earnings per share (Basic and Diluted EPS), another key profitability metric, was ₹4.15 in fiscal year 2024.

The company is also aiming to improve its balance sheet further by reducing its debt levels and improving its debt-to-equity ratio, with ₹50 crore from the net proceeds of this issue being allocated to reduce debt. Overall, the company is displaying a consistent and growing financial performance.

How It Stacks Up Against Competitors

Indo Farm Equipment Ltd., with a P/E ratio of 62.16, is valued higher than peers like Action Construction Equipment (49.25) and Escorts Kubota (31.87), indicating a premium valuation despite its smaller scale. Its sales revenue of ₹360.38 crore and net profit of ₹15.6 crore are significantly lower than those of ACE (₹3,079.9 crore, ₹365.69 crore) and Escorts Kubota (₹9,742.03 crore, ₹1,161.8 crore). However, Indo Farm’s operating profit margin (17.51%) surpasses ACE (14.27%) and Escorts Kubota (12.39%), reflecting efficient operations. While the company shows strong profitability for its size, its smaller market capitalization of ₹1,033.11 crore highlights limited market presence, making it a potential growth play but with valuation concerns.

Opportunities

Indo Farm Equipment Ltd. has opportunities to grow through its planned expansion of pick-and-carry crane manufacturing, supported by an investment of ₹70.07 crore. The company’s in-house NBFC provides financial flexibility, and its international presence, particularly in Africa and Asia, offers scope for market diversification. Additionally, plans to expand its dealer network beyond North India align with the rising demand for mechanized farming solutions and government policies supporting agricultural technology adoption.

Challenges

The company faces challenges such as the potential underutilization of its expanded crane manufacturing capacity if demand does not meet expectations. Its significant reliance on the Indian market exposes it to domestic market fluctuations, including the seasonal nature of agricultural demand tied to monsoon performance, which directly impacts equipment sales. Dependence on financing for tractor sales increases its sensitivity to credit and regulatory risks, while competition from established players like Mahindra & Mahindra and Escorts Kubota adds further pressure to its growth prospects.

Source: Company RHP, Chittorgarh.com, Groww

Note: This article is for informational purposes only and should not be considered as investment advice. All investment decisions should be made in consultation with a qualified financial advisor.

Unimech Aerospace IPO: Key Insights, Financial Highlights, and Investment Potential

Investment Opportunities in the Aerospace Sector

The bidding period runs from December 23rd to December 26th, 2024, with a price range of ₹745-₹785. The lot size is 19 units, requiring a minimum investment of ₹14,155, and the total issue size is 500Cr.

Unimech Aerospace and Manufacturing Limited is an engineering solutions company that specialises in the manufacturing and supply of critical parts. The company’s products include aero tooling, ground support equipment, electro-mechanical sub-assemblies, and other precision-engineered components. They cater to various industries, including aerospace, defence, energy, and semiconductor. Unimech possesses “build to print” capabilities, manufacturing products based on client designs, and “build to specifications” capabilities, where they assist clients in designing products. The company has manufacturing facilities in Bangalore.

Unimech Aerospace and Manufacturing Limited’s IPO includes a fresh issue of shares amounting to ₹250 Cr and an offer for sale (OFS) of existing shares also worth ₹250 Cr. The capital raised from the fresh issue is designated for several key purposes, including: funding capital expenditure for expansion, with ₹36.37 Cr allocated to the company and ₹43.89 Cr to its material subsidiary for purchasing machinery and equipment; funding working capital needs; and repayment or prepayment of borrowings of ₹40.00 Cr by the material subsidiary.

Unimech Aerospace IPO last GMP is ₹405. With the price band of 785.00, Unimech Aerospace IPO’s estimated listing price is ₹1190 (cap price + today’s GMP).The expected percentage gain/loss per share is 51.59%.

Financial Insights

Unimech Aerospace and Manufacturing Limited’s financials demonstrate significant growth across key metrics. Revenue from operations has increased from ₹36.35 Cr in Fiscal Year 2022 to ₹208.78 Cr in Fiscal Year 2024, and stood at ₹120.66 Cr for the six months ended September 30, 2024. The company’s EBITDA has also grown, from ₹7.73 Cr in Fiscal Year 2022 to ₹79.19 Cr in Fiscal Year 2024, with ₹48.83 Cr for the six months ended September 30, 2024. EBITDA margins were 21.25% in Fiscal Year 2022, 36.70% in Fiscal Year 2023, 37.93% in Fiscal Year 2024, and 40.47% for the six months ended September 30, 2024 . The profit after tax (PAT) has seen a considerable increase, from ₹3.39 Cr in Fiscal Year 2022 to ₹58.13 Cr in Fiscal Year 2024, with ₹38.68 Cr for the six months ended September 30, 2024. Profit margins have also improved, from 9.33% in Fiscal Year 2022 to 27.85% in Fiscal Year 2024, and 32.06% for the six months ended September 30, 2024.

Other key metrics include a Return on Capital Employed (ROCE) of 54.36% in Fiscal Year 2024 and a Return on Equity (ROE) of 53.53% in the same period. The company had a debt-equity ratio of 0.64 as of September 30, 2024 and 0.32 as of March 31, 2024.

How It Stacks Up Against Competitors

Unimech Aerospace and Manufacturing Ltd enters the market with a projected P/E ratio of 68.77, positioning it below several competitors such as Azad Engineering Ltd (P/E: 144.85) and MTAR Technologies Ltd (P/E: 136.8), indicating a relatively lower valuation. Despite a smaller revenue base of ₹208.78 Cr compared to larger peers like Dynamatic Technologies Ltd (₹1423.62 Cr) and MTAR Technologies (₹579.57 Cr), Unimech demonstrates impressive operational efficiency with an OPM of 37.97%, surpassing many competitors, except Data Patterns’ 43.44%. With a net profit of ₹58.13 Cr, Unimech is behind leaders such as Azad Engineering Ltd (₹69.74 Cr) and Data Patterns (₹185.14 Cr), but its robust margins suggest potential for profitability growth.

Compared to its closest peer in terms of market capitalization, Paras Defence & Space Technologies Ltd (₹4133.71 Cr), Unimech Aerospace and Manufacturing Ltd (₹3992.27 Cr) is valued slightly lower. While Unimech’s sales stand at ₹208.78 Cr compared to Paras’ ₹314.53 Cr, it compensates with significantly higher OPM margins of 37.97% and a competitive net profit of ₹58.13 Cr, demonstrating strong operational efficiency.

Opportunities and Challenges

Unimech Aerospace and Manufacturing Limited’s IPO offers considerable opportunities and is subject to certain challenges. The company’s strong financial performance is evident in its substantial revenue growth from ₹36.35 Cr in FY22 to ₹208.78 Cr in FY24, along with a significant increase in EBITDA from ₹7.73 Cr to ₹79.19 Cr. The IPO is aimed at supporting further growth through strategic allocation of funds for capital expenditure for expansion, working capital, and debt reduction.

Beyond these areas of investment, opportunities exist for the company to expand its global footprint, particularly in strategic regions. Furthermore, the company’s strategic partnership with Dheya Engineering Technologies Private Limited, where it has a 30% stake in the issued share capital, could lead to further growth.

The challenges include potential supply chain disruptions, rising material costs, and the need to adapt to rapid technological changes. The reliance on exports for over 90% of its sales also presents risks related to new market entry. Additionally, the company’s practice of absorbing minor cost fluctuations without adjusting product prices could lead to margin erosion and future pricing pressures. The company also faces the risk of customer expectation management, where customers may anticipate that Unimech will indefinitely absorb cost increases. Finally, it is essential that Unimech effectively manages its customer relationships and ensures the efficient use of IPO proceeds to support long-term sustainable growth.

Note: This article is for informational purposes only and should not be considered as investment advice. All investment decisions should be made in consultation with a qualified financial advisor.

Senores Pharmaceuticals Limited: Upcoming Pharma IPO

The IPO bidding will be open from December 20-24, 2024, with a price band set at ₹372-₹391 per share. The minimum investment required is ₹14,136 for 38 shares. The company aims to raise ₹582.11 crores through this IPO.

Senores Pharmaceuticals Limited is a global research-driven pharmaceutical company engaged in the development and manufacturing of a range of generic pharmaceutical products. The company primarily caters to regulated markets, such as the US, Canada, and the UK, and also has a presence in emerging markets across 43 countries. Senores Pharmaceuticals operates with a focus on speciality, underpenetrated, and complex pharmaceutical products. In addition to its generic pharmaceutical business, Senores manufactures critical care injectables and APIs. The company has several subsidiaries, including Senores Pharmaceuticals Inc. and Havix Group Inc., both located in the USA, and Ratnatris Pharmaceuticals Private Limited in India. The registered and corporate office is located in Ahmedabad, Gujarat, India.

The IPO includes a fresh issue of equity shares aggregating up to ₹500 Crores, along with an offer for sale of up to 2,100,000 equity shares.

Senores Pharmaceuticals intends to use the IPO proceeds for several purposes including ₹1,070 million for a new manufacturing facility in Atlanta via subsidiary Havix. They will also use ₹734.80 million to repay borrowings and ₹432.59 million for working capital needs, with additional funds going to subsidiaries and for acquisitions. Up to 35% of gross proceeds will go to inorganic growth and general corporate purposes.

Senores Pharmaceuticals IPO last GMP is ₹150. With the price band of 391.00, Senores Pharmaceuticals IPO’s estimated listing price is ₹541 (cap price + today’s GMP).The expected percentage gain/loss per share is 38.36%.

Financial Insights

Senores Pharmaceuticals Limited’s financial performance has varied across the periods detailed in the sources. For the six months ended September 30, 2024, the company’s revenue from operations was ₹181.02 Crores, with an EBITDA of ₹46.91 Crores and a profit margin of 13.23%. For the fiscal year 2024, the revenue was ₹214.52 Crores, with an EBITDA of ₹44.41 Crores, and a profit margin of 15.25%. In the fiscal year 2023, the revenue from operations stood at ₹35.34 Crores, with an EBITDA of ₹16.35 Crores, and a profit margin of 23.87%. The fiscal year 2022 saw the lowest revenue from operations at ₹14.17 Crores, with an EBITDA of ₹2.41 Crores and a profit margin of 7.00%.

The company’s Earnings Per Share (EPS) for fiscal year 2024 was ₹13.67 basic and ₹12.21 diluted. The Net Asset Value (NAV) per share was ₹66.96. The company’s return on equity (RoNW) was 23.60%. The debt-to-equity ratio of Senores was 1.07 compared to 0.00 for Ajanta, 0.09 for Alembic, 0.00 for Caplin Point, 0.04 for Gland and 1.17 for Strides.

Peer Comparison

Senores Pharmaceuticals stands out as a smaller player with significant growth potential but currently lags behind its peers in key metrics. Reporting the lowest sales (Rs. 214.52 Cr.) and net profit (Rs. 32.71 Cr.) among peers. Its operational efficiency, reflected by an OPM of 10%, is also the lowest compared to leaders like Caplin Point (33%). While these figures highlight challenges, they also indicate room for expansion and improvement, making Senores a potential high-risk, high-reward opportunity for investors.

Opportunities

Beyond the core opportunities previously discussed, Senores Pharmaceuticals has additional avenues for growth stemming from its strategic focus and market positioning. The company’s pursuit of abbreviated new drug application (ANDA) approvals, coupled with its focus on complex generic therapeutic segments, indicates a pathway to securing higher market share and potentially greater profit margins due to reduced competition. Their first-to-market advantage, such as with Chlorzoxazone 250mg, highlights the potential benefits of this approach. Moreover, the company’s vertical integration strategy, particularly its development of API capabilities, could lead to enhanced product offerings and stronger relationships with customers, creating diversified revenue streams. Finally, the company’s existing WHO-GMP-approved manufacturing facility in India allows it to market in 43 emerging market countries, providing a springboard to capitalise on growth in these markets. These elements, alongside the core plans, add to the overall potential for long-term growth if effectively managed.

Challenges

However, the company faces several potential challenges. Reliance on a limited number of contract development and manufacturing organisation (CDMO) and contract manufacturing operations (CMO) customers poses a risk. Fluctuations in interest rates could also impact the company’s operations. The pharmaceutical sector itself is subject to pricing pressures, market access complexities, and growing generic competition. Senores’ international operations also expose it to various management, legal, tax, and economic risks, particularly in the US, which constitutes a major revenue source. Furthermore, there is a risk of delays or cost increases in relation to the planned capital expenditures, which could negatively affect the company’s business. Ultimately, there is no guarantee that the company will be able to deploy the funds effectively or that its plans will lead to increased revenues.

Conclusion

In conclusion, while the IPO provides Senores Pharmaceuticals with the necessary capital for significant expansion and strategic acquisitions, investors should remain mindful of the inherent risks of the pharmaceutical industry. The company’s long-term success will rely on its ability to effectively manage these challenges and capitalise on the opportunities arising from its enhanced production capabilities and market presence in regulated markets.

Investment decisions should be made after consulting with a financial advisor.

Best financial advisor in Kochi, Kerala

Are you looking for the best financial advisor/wealth manager in Kochi, Kerala?? Here is why you are on the right page.At Square league, we are a team of Ex Bankers who have come together on a common platform to provide our clients a world class financial advisory and wealth management keeping the superlative interests of all stake holders in mind.
Maintaining financial health
Financial planning is a step-by-step approach to meet one’s life goals and maintain financial health. A financial plan acts as a guide as you go through life’s journey. Essentially, it helps you be in control of your income, expenses and investments such that you can manage your money and achieve your goals. Determine the status of your
current finances, viz., your income, expenses, debt, savings and investments. This is the first step in financial planning, as it gives you a good sense on the state of your finances and ways to improve.
How to create a successful financial plan??
FINANCIAL STABILITY INDEX
Financial stability does not always mean wealth, but financial sufficiency as defined by each person. In order to build a financial stability, it normally takes time by collecting enough funds for general living in the future and emergency incidents that may occur. Using the FSI tool one can measure the Financial Stability of an individual.
Understanding risk profile
The aim of the risk profiler is to gauge the optimal level of investment risk for an investor based on his required risk, risk tolerance and attitude. Your risk profile is essentially determined by objective factors (age, income,
number of dependents, security of your job) and subjective factors (risk behaviour intrinsic to each individual's psychology). Risk profiling, put simply, calculates the amount of risk you are ready to handle in case of a downturn. The output of the risk profiler forms the basis of a tailored financial plan that better reflects the investor’s perception of the acceptable trade-off between risk and return. An aggressive investor, or one with a high-risk tolerance, is more likely to risk losing money in order to get better results. A conservative investor, or one with a low-risk tolerance, tends to favour investments that will preserve his or her original investment.
Asset allocation
Investments need to be carefully planned and designed as per your risk taking capacities. This will affect the returns and hence the allocation of assets in your investment portfolio. Asset allocation involves dividing an investment portfolio among different asset categories, such as stocks, bonds, cash and cash equivalent, gold, mutual fund, real estate etc. The process of determining which mix of assets to hold in the investment
portfolio is a very personal one. The asset allocation that works best at any given point in life will depend largely on time horizon and ability to tolerate risk. Different asset class move in different directions. All types of asset classes hardly perform in tandem. One might assume that it is best to invest in mutual funds that are performing really well at a particular time with an aim to time the market. However, it is quite challenging for any individual to predict in which direction any asset class would move at any given point of time. For instance, when equities may be up, gold investment might go down and vice versa. So, it makes sense to allocate investments in a mix of asset classes. This is done so that if one set of asset classes or funds underperforms, the other asset
classes will balance the underperformance. Investing one’s portfolio in just one asset class or mutual fund scheme can be extremely risky. However, if an investor’s wealth is spread across asset classes, they tend to make better
returns.
Financial goals
Ask yourself: ‘what are the different financial goals I wish to achieve in life?’ Write them on a piece of paper. Don’t hesitate to put down any goal because no goal is too small or too big and channelize your finance as per priority. Planning ahead by setting financial goals is crucial for the immediate and long-term financial success of any individual. We tend to become more realistic about our finances and align it in line with the time frame in which we wish to achieve our goals. Depending on the stage of your life and your career, you might have different priorities that will affect your financial goals. List all your goals and mention the time frame in which you wish to achieve these goals. Using the ‘SMART’ strategy can help you set financial goals easily. SMART is an acronym for Specific, Measurable, Achievable, Realistic, Time-bound goals.
Wealth creation
The rise in the price of everyday items means that if you want to maintain or increase your current standard of living in the future, you need to create a sufficient corpus of wealth. You may also want to purchase a better car or a new house in the future. All this requires money, and it merely highlights the importance of wealth creation. It is possible to achieve these goals by carefully investing your money in the right avenues.
Estate planning
People, throughout their lives, work hard to create assets for their loved ones. But they don't plan the way the assets should be passed on to the next generation. An estate is all of the property a person owns or controls. The property in one's estate may consist of financial assets (e.g., bank accounts, stocks, bonds, or business interests), tangible personal assets (e.g., artwork, collectibles, or vehicles), immovable property (e.g., residential real estate, tea/timber rights), and intellectual property (e.g., royalties). Estate planning in simple terms refers to the passing assets / investments down from one generation to another. You decide how much of your estate – be it property(s), car(s), personal accolades, financial investments, etc. – you want to pass on to whom and how, after your demise. Thinking about your legacy and shaping your estate plan is an important part of the on-going financial planning process.
An estate plan aims to preserve the maximum amount of wealth possible for the intended beneficiaries and flexibility for the individual prior to death. A good estate plan is comprised of five key elements: Will, Trust(s), Power of Attorney, Health Care or Medical Directive and Beneficiary Designation.